Trial intelligence / Profile preview

Brolucizumab vs aflibercept ophthalmic therapy (Japan, Phase 2-3)

jRCT2080224986Phase 3Completed

Start
Dec 2019
Modality
scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01

Overview

Phase 3, randomised trial of brolucizumab in well-being (2 arms). Started Dec 2019; status: completed.

02

Drugs

brolucizumab
03

Conditions

well-being

Beyond the preview

Go deeper on jRCT2080224986.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080224986.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call